Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.
IM Cannabis Corp. reports developments tied to its medical cannabis platform serving patients in Israel and Germany. Company updates commonly address medical cannabis operations, regulatory and commercial positioning, operating and financial results, and the management of liquidity through note purchase agreements, convertible notes and common share purchase warrants.
Recurring IMCC news also includes Nasdaq listing-compliance notices, board and executive appointments, shareholder or governance matters, and disclosures related to material agreements and capital structure. The company’s announcements frame IM Cannabis as an international medical cannabis issuer with cross-border supply and compliance considerations in regulated cannabis markets.
IM Cannabis Corp. (CSE: IMCC, NASDAQ: IMCC) has provided details on its acquisition of the Panaxia online pharmacy and trading center license from Panaxia Pharmaceutical Industries Israel Ltd. for $7.2 million. This transaction consists of $2.9 million in cash and $4.3 million in shares. So far, IMC has completed the first closing and issued 246,007 shares at $3.68 each, valued at approximately $905,305.76. Additional share installments are expected over the next months, pending regulatory approval from the Israeli Ministry of Health.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) reported Q2 2021 revenues of $11.1 million, up 27% from Q1 2021. The company announced the acquisition of 51% of Vironna pharmacy for approximately $3.3 million, targeting the growing Arab consumer segment. With strong Q3 performance expected across regions, IMC anticipates further revenue growth, benefiting from acquisitions and medical sales boosts in Israel. Challenges included a 5% gross margin due to shipment delays and production issues, resolved this quarter, indicating potential for improved margins ahead.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) has entered a binding letter of intent with cbdMD, Inc. to exclusively import its products to Israel, pending regulatory approval. This partnership aims to capitalize on the anticipated growth of the Israeli CBD market, projected to reach US$475 million by 2025. Additionally, IMC provided updates on its previous acquisition of the Panaxia pharmacy, involving a total purchase price of $7.2 million, with $2.9 million paid in cash and $4.3 million through share issuance.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) announced the results from its annual general and special meeting held on July 28, 2021. A total of 37,108,584 shares were voted, representing 65.03% of outstanding shares. Shareholders approved all resolutions, including the appointment of directors and the re-appointment of auditors. Notable voting results included strong support for nominees Oren Shuster and Marc Lustig, receiving 96.19% of votes for their election. The company continues to strengthen its operations in Israel, Germany, and Canada.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) announces the acquisition of leading medical cannabis pharmacy Pharm Yarok and logistics provider Rosen High Way for approximately CAD$4.6 million. This acquisition, expected to enhance its vertical integration strategy in Israel, will consolidate assets with an annual revenue run rate of CAD$8 million and positive EBITDA of CAD$1 million. The closing is contingent upon necessary regulatory approvals and is anticipated to improve purchasing power and operational synergies.
IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) announced the completion of a new logistics center in Germany, enhancing operations of its EU-GMP subsidiary, Adjupharm. This 80,000-square-foot facility will enable internal supply chain management and increase cannabis storage capacity to seven tons. Preliminary Q2 revenue estimates range from $11 million to $12 million, reflecting a 30% sequential rise. Anticipated Q3 revenues are expected to be driven by increased sales in Israel, full quarter contributions from recent acquisitions, and renewed growth in Germany.
IM Cannabis Corp. (IMCC) announces significant updates regarding its operations in Germany and Israel. Its subsidiary, Adjupharm, has signed supply agreements with The Green Organic Dutchman and Natural MedCo to expand its medical cannabis product offerings. In recognition of its brand launch, IMC received the 'German Brand Award 2021.' Additionally, a bill for CBD legalization and cannabis decriminalization has been approved in Israel, indicating potential market growth. However, legal proceedings involving Focus Medical may pose risks.
IM Cannabis Corp. (NASDAQ:IMCC) has successfully completed its acquisition of MYM Nutraceuticals Inc. following the announcement made on April 1, 2021. The acquisition was finalized on July 9, 2021, resulting in IMC acquiring all MYM shares at a ratio of 0.022 IMC shares per MYM share. This transaction gives former MYM shareholders approximately 15% of IMC's total shares. It enhances IMC's distribution capabilities, particularly in Eastern Canada, and positions the company for growth in Israel and Germany. MYM will be delisted from the Canadian Securities Exchange.
IM Cannabis Corp. (NASDAQ:IMCC) announced that shareholders of MYM Nutraceutical Inc. overwhelmingly approved the acquisition of MYM, including its subsidiary Highland Grow. This court-approved arrangement, expected to close around July 9, 2021, will be immediately accretive to IMC's EBITDA. The acquisition promises over $4 million in annual synergies, enhanced distribution capabilities, and the integration of premium brands. MYM shareholders will receive 0.022 IMC shares for each MYM share held, with MYM shares to be delisted from the CSE.
Summary not available.